After exclusion of 42 patients [significant coronary artery disease (n = 15), NT‐proBNP <220 pg/mL (n = 14), cardiac amyloidosis (n = 13)], 254 patients were prospectively enrolled. The gene discussed is NPPB; the disease is cardiac amyloidosis.